Abstracts tagged "inflammatory rheumatic diseases"

Abstract Number: 1682 • ACR Convergence 2021
Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Johanna Sigaux¹, Sylvain Mathieu², Yann N guyen³, Pauline Sanchez⁴, Jean-Guillaume LETAROUILLY⁵, Martin Soubrier², sebastien czernichow⁶, Rene-Marc FLIPO⁷, Jeremie Sellam⁸ and Claire Daïen⁴, ¹Department of Rheumatology, Hôpital Avicenne, APHP, INSERM U1125, Université Sorbonne Paris Nord, Bobigny, France, ²Department of Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ³Department of Internal Medicine, Hôpital Beaujon, APHP nord, Université de Paris, F-92100 Clichy, France, Paris, France, ⁴Department of Rheumatology, CHU de Montpellier, & University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier FRANCE University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier, France, ⁵Rheumatology Department, University Hospital of Lille, Lille, France, ⁶Department of Nutrition, Specialized Obesity Center, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France, ⁸INSERM UMRS_938, Sorbonne Université, St-Antoine Hospital, Paris, France, Paris, France
Background/Purpose: This systematic literature review and meta-analysis aimed to better estimate the effect of oral supplementation with polyunsaturated fatty acid (PUFA; omega (n)-3 and n-6)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].